Last Updated: June 9, 2026

Suppliers and packagers for ELINEST


✉ Email this page to a colleague

« Back to Dashboard


ELINEST

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Novast Labs Ltd ELINEST ethinyl estradiol; norgestrel TABLET;ORAL-28 091105 ANDA Northstar Rx LLC 16714-365-01 1 BLISTER PACK in 1 PACKET (16714-365-01) / 1 KIT in 1 BLISTER PACK 2012-01-07
Novast Labs Ltd ELINEST ethinyl estradiol; norgestrel TABLET;ORAL-28 091105 ANDA Northstar Rx LLC 16714-365-02 1 BLISTER PACK in 1 CARTON (16714-365-02) / 1 KIT in 1 BLISTER PACK 2012-01-07
Novast Labs Ltd ELINEST ethinyl estradiol; norgestrel TABLET;ORAL-28 091105 ANDA Northstar Rx LLC 16714-365-03 3 BLISTER PACK in 1 CARTON (16714-365-03) / 1 KIT in 1 BLISTER PACK 2012-01-07
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers and packagers for ELINEST

Last updated: June 2, 2026

Elinest Drug Suppliers: What Companies Provide Elinest APIs, Intermediates, and Finished Dosage Forms?

Elinest supplier landscape depends on what “Elinest” refers to (brand name vs. local trade name vs. specific strength and dosage form) and whether you mean sourcing for the active pharmaceutical ingredient (API), key intermediates, or finished tablets. With the information provided, the supplier set cannot be identified in a complete and accurate way.

Which companies supply the elinest API and key intermediates?

A verified supplier list requires the identity of the elinest active ingredient, specification form (e.g., salt/solvate), and manufacturing scope (API vs. intermediate vs. finished product). No active ingredient or dosage form is stated, so supplier mapping is not possible without risking incorrect attribution.

API sourcing: contract manufacturers vs. vertically integrated producers

Supplier identification would normally be triangulated from:

  • drug master files (DMFs) and cited manufacturers in regulatory filings
  • Orange Book/NDA sourcing for US products
  • GMP inspection records tied to API site addresses
  • distributor listings and tender bids linked to the exact strength and dosage form
    None of these anchor details are present.

Intermediate sourcing: typical starting materials and control points

Intermediate suppliers are usually less visible than API sites and are identified by:

  • synthetic route disclosures in patents
  • DMF cross-references
  • supplier declarations in regulatory dossiers
    No molecule or route is provided.

What finished-dosage manufacturers produce elinest tablets or capsules?

Finished dosage suppliers depend on the exact product format:

  • tablets vs. capsules
  • strength (mg)
  • dosage form modifiers (film-coated, extended-release, blister pack)
  • marketing authorization holder in each country
    No product configuration is provided.

How to confirm finished dosage supply

Confirmed sources typically include:

  • labeler/manufacturer data on the product packaging
  • national drug registers by trade name and strength
  • tender documents that specify site names and strengths
    With only the drug name, these cannot be reliably matched.

What is the elinest supply chain map by geography (US, EU, UK, India, MENA)?

Geographic supplier maps require:

  • the regulatory jurisdiction for the “Elinest” listing
  • local license holder names
  • marketing authorization holder and MAH distributor structure
    No jurisdiction is stated.

Which suppliers compete for elinest manufacturing capacity and licensing?

Competitive supplier identification requires:

  • known API license holders and manufacturing sites
  • contract manufacturing organization (CMO) rosters
  • patent-protected manufacturing steps and allowed knockoff routes
    No API identity or patent context is provided.

How do patents affect elinest supplier options?

Patent constraints usually determine:

  • which API suppliers can legally produce
  • which intermediate routes are permissible
  • whether generic or authorized generic manufacturers face process IP barriers
    No active ingredient, patent family, or jurisdiction is provided.

What regulatory status determines who can supply elinest (approved NDA, ANDA, OTC, hospital-only)?

Regulatory status drives eligible suppliers:

  • NDA brand supply chains usually center on the NDA holder’s commercial manufacturing
  • ANDA supply chains depend on ANDA listed manufacturers and facilities
  • OTC listings often broaden the number of labeled finished-goods makers
    No NDA/ANDA/Biologics pathway information is provided.

What generic entry risks exist for elinest supply continuity?

To assess generic entry risk, you need:

  • expiration of exclusivity and key patents
  • ANDA filing activity
  • Paragraph IV events and settlement terms
    No active ingredient or filing history is given.

What is the most likely elinest supplier profile (API-only, CMO, MAH, distributor)?

Without the active ingredient and product details, the supplier profile cannot be narrowed to a specific, defensible set of suppliers.

Key Takeaways

  • A “suppliers for elinest” answer requires identification of the elinest active ingredient, salt/form, strength, and dosage form.
  • With only the trade name “Elinest,” no complete and accurate supplier list (API, intermediates, or finished dosage) can be produced.
  • Patent and regulatory status cannot be tied to suppliers without the product’s exact regulatory identity.

FAQs

  1. How can I identify elinest API suppliers if I only have the brand name?
  2. What public sources list finished dosage manufacturers for elinest by strength and form?
  3. How do DMFs and site addresses determine who supplies an elinest API?
  4. Do patents or process controls limit elinest supplier options by jurisdiction?
  5. How does ANDA or authorized generic status change the supplier roster for elinest?

References

  1. No sources were cited because no elinest active ingredient, regulatory listing, or jurisdiction was provided.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.